Monoclonal antibody · Antagonist of NKG2A (killer cell lectin-like receptor C1) (KLRC1) · developed by MedImmune LLC
Monalizumab is a humanized IgG4 monoclonal antibody that binds the inhibitory receptor NKG2A on natural killer cells and T lymphocytes, blocking its interaction with HLA-E on tumor cells. This releases NK and CTL cytotoxic activity against cancer cells. It is being studied in squamous cell carcinoma of the head and neck and of the oral cavity.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04590963 | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | Active not recruiting | IPHA |
| NCT02331875 | Phase 1/2 | Squamous Cell Carcinoma of the Oral Cavity | Terminated | IPHA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Squamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma of the Oral Cavity
Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →